Academic Perspectives for LR-MDS Treatment in the Community
Panelists discuss key learnings from recent studies on lower-risk myelodysplastic syndrome (LR-MDS) treatment, identify remaining knowledge gaps, and offer final takeaways, including their thoughts on the role of luspatercept in the evolving LR-MDS treatment landscape, clinical pearls for community oncologists, and major unanswered questions that could improve outcomes for LR-MDS and anemia management in the future.
- Given all the treatment strategies and key updates discussed today, what are your overall thoughts on luspatercept in the LR-MDS treatment landscape?
- What clinical pearls can you leave for community oncologists?
- In your opinion, what are the major unanswered questions that could continue to improve outcomes for LR-MDS treatment and anemia management?
- Please discuss any emerging concepts or other considerations that could influence treatment in the coming years.
Recent Videos
Related Content
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Article
Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
